ISDA: 7LJR

Deposition Date 2021-01-30

Release Date 2021-03-31

Last Version Date 2024-03-06

Entry Detail

PDB ID:

7LJR

Keywords:

VIRAL PROTEIN/IMMUNE SYSTEM

Title:

SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab

Biological Source:

Source Organism(s):

Severe acute respiratory syndrome coronavirus 2 (Taxon ID: 2697049)
Homo sapiens (Taxon ID: 9606)

Expression System(s):

Homo sapiens

Method Details:

Experimental Method:

ELECTRON MICROSCOPY

Resolution:

3.66 Å

Aggregation State:

PARTICLE

Reconstruction Method:

SINGLE PARTICLE

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Spike glycoprotein
Gene (Uniprot):S
Chain IDs:A, B, C
Chain Length:1288
Number of Molecules:3
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTC2 Pfam ID:PF16451, PF09408, PF19209, PF01601

Polymer Type:polypeptide(L)
Molecule:Fab DH1043 heavy chain
Chain IDs:D (auth: S)
Chain Length:472
Number of Molecules:1
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Molecule:Fab DH1043 light chain
Chain IDs:E (auth: T)
Chain Length:233
Number of Molecules:1
Biological Source:Homo sapiens

Ligand Molecules

Primary Citation

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates.

Li, D, Edwards, R.J, Manne, K, Martinez, D.R, Schafer, A, Alam, S.M, Wiehe, K, Lu, X, Parks, R, Sutherland, L.L, Oguin, T.H, McDanal, C, Perez, L.G, Mansouri, K, Gobeil, S.M.C, Janowska, K, Stalls, V, Kopp, M, Cai, F, Lee, E, Foulger, A, Hernandez, G.E, Sanzone, A, Tilahun, K, Jiang, C, Tse, L.V, Bock, K.W, Minai, M, Nagata, B.M, Cronin, K, Gee-Lai, V, Deyton, M, Barr, M, Von Holle, T, Macintyre, A.N, Stover, E, Feldman, J, Hauser, B.M, Caradonna, T.M, Scobey, T.D, Moody, M.A, Cain, D.W, DeMarco, C.T, Denny, T.N, Woods, C.W, Petzold, E.W, Schmidt, A.G, Teng, I.T, Zhou, T, Kwong, P.D, Mascola, J.R, Graham, B.S, Moore, I.N, Seder, R, Andersen, H, Lewis, M.G, Montefiori, D.C, Sempowski, G.D, Baric, R.S, Acharya, P, Haynes, B.F, Saunders, K.O.Show

Biorxiv ? ? ? (2021)

PMID: 33442694 DOI: 10.1101/2020.12.31.424729

Abstact

SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) and the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV-1 infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-γ (FcγR)-mediated enhancement of virus infection in vitro , while five non-neutralizing NTD antibodies mediated FcγR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Nonetheless, three of 31 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated bronchoalveolar lavage inflammatory cytokines. Thus, while in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo , increased lung inflammation can occur in SARS-CoV-2 antibody-infused macaques.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form